KBC Group
ADMA icon

KBC Group’s ADMA Biologics ADMA Stock Holding History

KBC Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65K Hold
7,791
– – ﹤0.01% 1620
2026
Q1 		$70K Hold
7,791
– – ﹤0.01% 1503
2025
Q4 		$142K Hold
7,791
– – ﹤0.01% 1072
2025
Q3 		$114K Hold
7,791
– – ﹤0.01% 1186
2025
Q2 		$142K Sell
7,791
-3,426
-31% -$69.9K ﹤0.01% 1014
2025
Q1 		$223K Buy
11,217
+1,154
+11% +$20K ﹤0.01% 1011
2024
Q4 		$173K Buy
10,063
+3,513
+54% +$66.1K ﹤0.01% 1209
2024
Q3 		$131K Hold
6,550
– – ﹤0.01% 1120
2024
Q2 		$73K Buy
+6,550
New +$54.9K ﹤0.01% 1373

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KBC Group's ADMA Position: Q2 2026 in Review

KBC Group held its ADMA Biologics (ADMA) position steady in Q2 2026 at 7,791 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

KBC Group first reported a position in ADMA in Q2 2024 and has held it in 9 quarters since. The position peaked at $223K in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • KBC Group held 7,791 shares of ADMA Biologics worth $65K as of Q2 2026.
  • KBC Group left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1620 holding.
  • KBC Group first reported a position in ADMA Biologics in Q2 2024 and has held it in 9 quarters since.
  • KBC Group's ADMA Biologics position peaked at $223K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.